DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,265 | +1.3% | 9,130 | -2.0% | 1.19% | +8.1% |
| Q2 2023 | $2,236 | -6.8% | 9,319 | -2.1% | 1.10% | -7.6% |
| Q1 2023 | $2,400 | -6.7% | 9,521 | -1.8% | 1.19% | -9.2% |
| Q4 2022 | $2,573 | -99.9% | 9,695 | +4.3% | 1.31% | -3.8% |
| Q3 2022 | $2,400,000 | +1.4% | 9,291 | -0.5% | 1.36% | +6.7% |
| Q2 2022 | $2,368,000 | -14.1% | 9,339 | -0.6% | 1.28% | -0.2% |
| Q1 2022 | $2,756,000 | -12.7% | 9,396 | -2.1% | 1.28% | -7.0% |
| Q4 2021 | $3,158,000 | +7.4% | 9,599 | -0.6% | 1.37% | -3.3% |
| Q3 2021 | $2,940,000 | -7.0% | 9,659 | -18.0% | 1.42% | -7.9% |
| Q2 2021 | $3,161,000 | +15.9% | 11,779 | -2.8% | 1.54% | +10.1% |
| Q1 2021 | $2,727,000 | -2.4% | 12,116 | -3.7% | 1.40% | -6.9% |
| Q4 2020 | $2,794,000 | -3.3% | 12,577 | -6.2% | 1.50% | -12.9% |
| Q3 2020 | $2,888,000 | +3.1% | 13,414 | -15.3% | 1.73% | +1.6% |
| Q2 2020 | $2,801,000 | +20.3% | 15,839 | -5.9% | 1.70% | +3.3% |
| Q1 2020 | $2,329,000 | -15.5% | 16,830 | -6.3% | 1.65% | +13.0% |
| Q4 2019 | $2,755,000 | +5.1% | 17,953 | -1.1% | 1.46% | -0.5% |
| Q3 2019 | $2,621,000 | -0.8% | 18,147 | -1.8% | 1.46% | -2.0% |
| Q2 2019 | $2,642,000 | +5.0% | 18,487 | -3.0% | 1.50% | +2.6% |
| Q1 2019 | $2,516,000 | +20.5% | 19,059 | -5.9% | 1.46% | +4.7% |
| Q4 2018 | $2,088,000 | -6.4% | 20,250 | -1.4% | 1.39% | +8.6% |
| Q3 2018 | $2,231,000 | +9.6% | 20,531 | -0.5% | 1.28% | +2.2% |
| Q2 2018 | $2,035,000 | +1.5% | 20,627 | +0.8% | 1.25% | -1.3% |
| Q1 2018 | $2,004,000 | +2.3% | 20,467 | -3.0% | 1.27% | +10.1% |
| Q4 2017 | $1,958,000 | +8.4% | 21,098 | +0.2% | 1.15% | +2.9% |
| Q3 2017 | $1,807,000 | +2.4% | 21,066 | +0.7% | 1.12% | -0.9% |
| Q2 2017 | $1,765,000 | -3.2% | 20,913 | -1.9% | 1.13% | -3.7% |
| Q1 2017 | $1,823,000 | +13.2% | 21,318 | +3.0% | 1.18% | +6.9% |
| Q4 2016 | $1,611,000 | 0.0% | 20,698 | +0.7% | 1.10% | -1.0% |
| Q3 2016 | $1,611,000 | -21.9% | 20,550 | +0.6% | 1.11% | -21.7% |
| Q2 2016 | $2,063,000 | +5.3% | 20,423 | -1.1% | 1.42% | +4.6% |
| Q1 2016 | $1,959,000 | +46.7% | 20,653 | +43.7% | 1.36% | +46.6% |
| Q4 2015 | $1,335,000 | +3.6% | 14,369 | -5.0% | 0.92% | +0.5% |
| Q3 2015 | $1,289,000 | -3.4% | 15,126 | -3.0% | 0.92% | +4.6% |
| Q2 2015 | $1,335,000 | -2.3% | 15,596 | -3.1% | 0.88% | +0.1% |
| Q1 2015 | $1,366,000 | -3.4% | 16,090 | -2.4% | 0.88% | -2.3% |
| Q4 2014 | $1,414,000 | +10.0% | 16,492 | -2.6% | 0.90% | +3.3% |
| Q3 2014 | $1,286,000 | -8.7% | 16,932 | -5.4% | 0.87% | -7.1% |
| Q2 2014 | $1,409,000 | -0.4% | 17,892 | -5.1% | 0.94% | +0.6% |
| Q1 2014 | $1,414,000 | -4.7% | 18,847 | -1.9% | 0.93% | -5.5% |
| Q4 2013 | $1,483,000 | +7.2% | 19,212 | -3.7% | 0.98% | -0.4% |
| Q3 2013 | $1,383,000 | +2.1% | 19,955 | -6.7% | 0.99% | +3.0% |
| Q2 2013 | $1,354,000 | – | 21,392 | – | 0.96% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |